Compare AstraZeneca plc (AZN) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Wahed FTSE USA Shariah ETF — how do they compare? AstraZeneca plc trades at $158.41 (market cap $248.14B), while Wahed FTSE USA Shariah ETF trades at $72.96. The key difference: AstraZeneca plc pays a 2.01% dividend while Wahed FTSE USA Shariah ETF pays none, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | HLAL | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $209.48 | $73.60 |
52-Week Low | $147.06 | $55.52 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
HLAL trades at $72.93, showing minimal daily movement with a slight 0.06% decline. Technical indicators present a mixed picture with bullish moving averages but neutral oscillators, while the stock lacks comprehensive fundamental data for traditional valuation metrics. The upcoming dividend of $0.02 per share scheduled for June 2026 provides a modest income component.
The stock's outlook remains uncertain due to limited financial disclosures. Investment opportunity hinges on future earnings visibility and market positioning, while primary risks include information gaps and market volatility. Further fundamental analysis requires updated SEC filings and earnings reports to assess true valuation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →
